Cargando…
Oncolytic herpes simplex virus and temozolomide synergistically inhibit breast cancer cell tumorigenesis in vitro and in vivo
The oncolytic herpes simplex virus (HSV) G47Δ can selectively eliminate glioblastoma cells via viral replication and temozolomide (TMZ) has been clinically used to treat glioblastoma. However, the combined effect of G47Δ and TMZ on cancer cells, particularly on breast cancer cells, remains largely u...
Autores principales: | Fan, Jingjing, Jiang, Hua, Cheng, Lin, Ma, Binlin, Liu, Renbin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751368/ https://www.ncbi.nlm.nih.gov/pubmed/33376532 http://dx.doi.org/10.3892/ol.2020.12360 |
Ejemplares similares
-
Oncolytic herpes simplex virus infects myeloma cells in vitro and in vivo
por: Ghose, Jayeeta, et al.
Publicado: (2021) -
Oncolytic herpes simplex virus and immunotherapy
por: Ma, Wenqing, et al.
Publicado: (2018) -
Treatment of human hepatocellular carcinoma by the oncolytic herpes simplex virus G47delta
por: Wang, Jiani, et al.
Publicado: (2014) -
Retargeting Strategies for Oncolytic Herpes Simplex Viruses
por: Campadelli-Fiume, Gabriella, et al.
Publicado: (2016) -
Antitumor effects of oncolytic herpes simplex virus type 2 against colorectal cancer in vitro and in vivo
por: Yin, Lei, et al.
Publicado: (2017)